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Abstract
Background: Mammary tumors are the most common tumor type in both human and canine females. In women,
carriers of mutations in BRCA2, a tumor suppressor gene product, have a higher risk of breast cancer. Canine
BRCA2 has also been suggested to have a relationship with mammary tumors. However, clearly deleterious BRCA2
mutations have not been identified in any canine mammary tumors, as appropriate methods to detect mutations
or a consensus BRCA2 sequence have not been reported.
Findings: For amplification and sequencing of BRCA2, we designed 14 and 20 PCR primer sets corresponding to
the BRCA2 open reading frame (ORF) and all 27 exons, respectively, including exon-intron boundaries of the canine
BRCA2 regions, respectively. To define the consensus canine BRCA2 ORF sequence, we used established methods
to sequence the full-length canine BRCA2 ORF sequence from two ovaries and a testis obtained from individual
healthy mongrel dogs and partially sequence BRCA2 genomic sequences in 20-56 tumor-free dogs, each aged over
6 years. Subsequently, we compared these sequences and seven previously reported sequences, and defined the
most common base sequences as the consensus canine BRCA2 ORF sequence. Moreover, we established a
detection method for identifying splicing variants. Unexpectedly, we also identified novel splicing variants in
normal testes during establishment of these methods.
Conclusions: The present analysis methods for determining the BRCA2 base sequence and for detecting BRCA2
splicing variants and the BRCA2 ORF consensus sequence are useful for better understanding the relationship
between canine BRCA2 mutation status and cancer risk.
Findings
Mammary tumors are the most common tumor type in
both human and canine females, constituting about half
of all tumors in female dogs [1-4]. Furthermore, approxi-
mately half of canine mammary tumors are malignant
[5,6]. In humans, heritable breast cancers have been
linked with mutations in the breast cancer susceptibility
gene BRCA2. Genetic analysis, including detection of
deleterious mutations and splicing variants, to identify
BRCA2 mutation carriers is strongly advocated, as the
lifetime risk of breast cancer is high (81-88%) for females
carrying a BRCA2 mutation [7,8].
In a recent study, it was suggested that the canine
BRCA2 gene locus is associated with mammary tumors
based on single nucleotide polymorphism analysis of an
intronic marker [9,10]. Consistent with this notion, we
previously showed that loss of heterozygosity, which is
one of the mechanisms of BRCA2 inactivation, was pre-
sent in a mammary tumor [11]. Canine BRCA2 missense
mutations have also been reported in mammary tumors
[11-13]. However, clearly deleterious mutations in the
canine BRCA2 sequence have not been identified in
mammary tumors due to the lack of appropriate methods
to detect such mutations. Furthermore, a full-length con-
sensus canine BRCA2 open reading frame (ORF)
sequence has not been defined, as full-length canine
BRCA2 has only been identified in a single sample [14].
Determination of the base sequence of BRCA2 in a
tumor sample and of this sequence comparison with the
BRCA2 consensus sequence is the most standard method
for detecting mutations in tumor samples in humans.
During the course of our present study, one study
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BRCA2, but they used many primer sets (about 50 sets)
a n da m p l i f i e ds e q u e n c eo n l yf r o mg e n o m i cD N A[ 1 5 ] .
To establish a more efficient mutation analysis method
for cDNA and genomic DNA that requires fewer primer
sets, we designed 14 and 20 primer sets in order to
sequence the BRCA2 ORF and all 27 exons, respectively,
including the exon-intron boundaries of the canine
BRCA2 regions. All PCR targets were successfully ampli-
fied, and were sufficient to determine DNA base
sequences (Figure 1A and 1B).
Some splicing variants of tumor suppressor genes (e.g.,
BRCA2) in tumor tissue have been associated with tumori-
genesis because these splicing variants often lead to frame-
shift mutations [16,17]. Thus, we next designed five
primer sets for detecting splicing variants from cDNA
(Figure 1C). All PCR targets were successfully amplified,
and the predicted sizes of PCR products were confirmed.
During the establishment of this method, we unexpectedly
identified splicing variants between exon 10 and exon 14
in normal testes (Figure 1C and 2). These transcripts
skipped most of exon 11, leading to frameshift mutations
(Figure 2).
To define the consensus canine BRCA2 ORF, we
sequenced the full-length canine BRCA2 ORF in two ovar-
ies and a testis obtained from individual healthy mongrel
dogs using the method described here. We identified six
single nucleotide variations (516 T > C, 1366 T > G, 2428
T > G, 2609A > C, 4481A > C and 8257 T > C) and two
insertion/deletion polymorphisms (7126ins/delGTT and
10204ins/delAAA) (Accession numbers: AB622997,
AB622998 and AB622999). None of these variations
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Figure 1 PCR products amplified by each primer set.( A) cDNA samples prepared from total RNA of each mammary gland were amplified.
(B) Genomic DNA from each mammary gland was amplified. (C) Splicing variants of the cDNA from total RNA of the mammary gland and testis
were amplified. Primer sets for each lane are shown in Table 1. The “M” indicates the molecular size marker (1-kbp DNA ladder; New England
Biolabs). Arrowhead and “*” indicate novel BRCA2 transcript and non-specific PCR products, respectively.
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mine the most common base sequences and generate a
consensus canine BRCA2 ORF sequence, we compared
these three new sequences (six alleles) and the seven pre-
viously reported sequences (Accession numbers:
AB043895.5, NC_006607.2, Z75664 and FJ464397-
FJ464400) (Table 2). The four variations (516 T (103I),
2428 T (740 G), 4481A (1425 T), and 8257 T (2683I))
could be defined as consensus base sequences, but the
other four variations (1366 T > G, 2609A > C (K801Q),
7126ins/delGTT, and 10204ins/delAAA) could not be
defined as such because the frequencies between the
major and minor alleles in each variation were nearly iden-
tical. We therefore sequenced these four variations in
genomic DNA from 20-23 normal blood samples from
tumor-free dogs aged over 6 years; the methods described
here were used (Tables 3 and 4). We finally defined the
most common base sequences as the consensus canine
BRCA2 ORF sequence (Table 2). The 10204insAAA varia-
tion was consensus sequence in dogs, but in four minia-
ture Dachshunds this variation was determined to be a
minor variation (allele ratio; del:ins = 6:2, Table 4).
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Figure 2 Identification of splicing variants within exon 11 in normal testes. The splicing variants identified in normal testes lacked a large
portion of exon 11. (A) To confirm the presence of a novel BRCA2 transcript, splicing variants of the cDNA from total RNA of the testes were
amplified using nested PCR. (B-E) Electropherogram showing the direct sequencing data and overview of the novel BRCA2 transcript that lacked
nucleotides 2390 to 6429 (B), 2390 to 6429 and 6588 to 6908 (C), 2390 to 3380, and 4649 to 6429 (D) and 2085 to 2321 and 2390 to 6429 (E)
from Testis-1, -3, -4, and -5, respectively. The Testis-1 was the same sample used to generate the data in Figure 1C. Primer sets for each lane are
shown in Table 1. The “M” indicates the molecular size marker (1-kbp DNA ladder). Arrowheads indicate novel BRCA2 transcripts.
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Page 3 of 10Table 1 Nucleotide base sequences of primers
Primer sets Forward Reverse Annealing
temperature
Elongation
time
Lane
Number
Expected sizes
For amplification of cDNA 1 5’-GCGGCACCTCGGAAGGC-3’ 5’-CCCCAAACTTTGACTTTTAGC-3’ 60°C 1 min Figure 1
A1
834 bp
25 ’-GATCGGTTTATCCCTTGTGGTC-3’ 5’-CTTCAGGTTCTTTAAAGTTTGG-3’ 60°C 1 min Figure 1
A2
865 bp
35 ’-CTGAAGGGATGTCCAATGC-3’ 5’-ATATTTTATATGATTCTTTTCCTC-3’ 56.1°C 1 min Figure 1
A3
850 bp
45 ’-CCAGTCTGTTAACTCCTAGC-3’ 5’-GGATAATGTTCCTCAATATCTTTG-3’ 60°C 1 min Figure 1
A4
826 bp
55 ’-ACAGCTTCTAATAAAGAGATAAA AC-3’ 5’-GCCGGCATTTATTATTTTTC-3’ 56.1°C 1 min Fig. 1 A
5
850 bp
65 ’-GTTTCTCCTCAAGCAAATACAA-3’ 5’-ATTTTTTACTTTGTCCAAAGATTCC-3’ 60°C 1 min Figure 1
A6
873 bp
75 ’-CTGATCCTGCAGCAAAGACC-3’ 5’-GAAAAACCAATGTTTTTTCTCTCTC-3’ 59.2°C 1 min Figure
1A 7
908 bp
85 ’-CATTCTAGTGAAGTGTATAATAA
ATCAG-3’
5’-CTGTCCTAAATCCAGAGAAAGC-3’ 50.8°C 1 min Figure 1
A8
919 bp
95 ’-AGTATCACTTAAAGATAATGAAG AAC-
3’
5’-CTTTTAGGATGCCGTCTGG-3’ 50°C 1 min Figure 1
A9
887 bp
10 5’-CCCCCAATTAAAAGAAACTTG-3’ 5’-GCCAATTGTATTCCTTCTCC-3’ 53.7°C 1 min Figure 1
A1 0
905 bp
11 5’-CCTCTGCATGTTCTCATAAAC-3’ 5’-GGGTATGCTCTTTGAACAACTAC-3’ 60°C 1 min Figure 1
A1 1
886 bp
12 5’-CATGGAGCAGAACTGGTAGG-3’ 5’-GTGTAAGGTTTAATAATGTCTTCA-3’ 50°C 1 min Figure 1
A1 2
1094 bp
13 5’-CCTATCCCAAGTTTATCAGCC-3’ 5’-CAGACACAAGTTGATGTTCTCC-3’ 60°C 1 min Figure 1
A1 3
959 bp
14 5’-GAAGGCATTTCAGCCACCACG-3’ 5’-CAATCACACTAGAATCATAAAAAGG-3’ 60°C 1 min Figure 1
A1 4
978 bp
For amplification of
genomic DNA
exon 1-2 5’-GCCCCCTGCCCAGAACCC-3’ 5’-CTTTTCAGCAAGCATGCACAGTTACG-3’ 60°C 2 min Figure 1
B1
1193 bp
exon 3 5’-CTACAGTCAAAATGTCAAGCG-3’ 5’-CACAATTAACAATAGATCTGGGAG-3’ 60°C 1 min Figure 1
B2
430 bp
exon 4-7 5’-ATAAGAATAAAAACTTCCAGAGAATG-3’ 5’-ATTATCTTTTCATATATTCTTTTTGTC-3’ 60°C 2 min Figure 1
B3
1384 bp
exon 8-9 5’-GTAGTATATGTGACTTTTGATGTCTG-3’ 5’-GGAAAAGCAATGTATTTTCTCTTT-3’ 60°C 2 min Figure 1
B4
615 bp
exon 10 5’-CTTTAAATACTGCCTTATGGGCTA-3’ 5’-GTCACCATCCCTAAAACTATATGC-3’ 60°C 2 min Figure 1
B5
1311 bp
exon 11-a 5’-GTCACTTTGTGTCTTCATGC-3’ 5’-GGATAATGTTCCTCAATATCTTTG-3’ 56.4°C 2 min Figure 1
B6
1246 bp
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0Table 1 Nucleotide base sequences of primers (Continued)
exon 11-b
(same as
primer set 5)
5’-ACAGCTTCTAATAAAGAGATAAAAC-3’ 5’-GCCGGCATTTATTATTTTTC-3’ 56.4°C 1 min Figure 1
B7
850 bp
exon 11-c(same
as primer set 6)
5’-GTTTCTCCTCAAGCAAATACAA-3’ 5’-GATTTTTTACTTTGTCCAAAGATTCC-3’ 60°C 1 min Figure 1
B8
873 bp
exon 11-d
(same as
primer set 7)
5’-CTGATCCTGCAGCAAAGACC-3’ 5’-GAAAAACCAATGTTTTTTCTCTCTC-3’ 59.2°C 1 min Figure 1
B9
908 bp
exon 11-e 5’-CATTCTAGTGAAGTGTATAATAAATCAG-
3’
5’-ATTCCCCTAAACTATACATAAAAG-3’ 56.4°C 2 min Figure 1
B1 0
1720 bp
exon 12 5’-CAATTCTTTAGTTTTAAAAAATGG GC-3 5’-
GAAAAAGCTTAGAAAAAGAACTTAAAAAATAC-
3’
59.2°C 1 min Figure 1
B1 1
275 bp
exon 13 5’-
GTAAATGTTTATAATGTGTAATATACAGGC-
3’
5’-CTGTACCTTCCCTACACTATATTAGTAG-3’ 60°C 1 min Figure 1
B1 2
230 bp
exon 14-15 5’-CCAAACTTAAATATTTTCTCCTC-3’ 5’-CAGGGATCCCAGTCTATTC-3’ 60°C 2 min Figure 1
B1 3
1213 bp
exon 16 5’-GCAGCAAACCCTTGAATGTAG-3’ 5’-GTCAGGTGAACCGTAATGTG-3’ 60°C 1 min Figure 1
B1 4
552 bp
exon 17-8 5’- GGTCTTGTACAGTGTAGTGTTTG-3’ 5’-GTTTTTAAGCAATGGAGCATC-3’ 59.2°C 2 min Figure 1
B1 5
1258 bp
exon 19-20 5’- CCATCATGTTTAAATTGAAGTCTC-3’ 5’-CAATTACAGAGGTTAAATCAGAAGCC-3’ 59.2°C 2 min Figure 1
B1 6
739 bp
exon 21-24 5’-CTCGATATTTGATTCACCAGC-3’ 5’-CAACAGTCCCTTCCTAACCC-3’ 60°C 2 min Figure 1
B1 7
1739 bp
exon 25 5’- CAGTATCACTTTTTCTACATTTTG GTC-
3’
5’-CCCAATTTTCACAGAAGCCAC-3’ 59.2°C 1 min Figure 1
B1 8
471 bp
exon 26 5’-GGCTTCCATAGATGTTAGATG-3’ 5’-GGACAACTTGGGATCATTTGC-3’ 50.8°C 1 min Figure 1
B1 9
337 bp
exon 27 5’- GCTAAATTGCTGATGTTTTCTAC-3’ 5’-CTGCTGAGTCCTCTAATAAGGC-3’ 60°C 2 min Figure 1
B2 0
1437 bp
exon 25 5’- CAGTATCACTTTTTCTACATTTTGGTC-3’ 5’-CCCAATTTTCACAGAAGCCAC-3’ 59.2°C 1 min Figure 1
B1 8
471 bp
exon 26 5’-GGCTTCCATAGATGTTAGATG-3’ 5’-GGACAACTTGGGATCATTTGC-3’ 50.8°C 1 min Figure 1
B1 9
337 bp
exon 27 5’- GCTAAATTGCTGATGTTTTCTAC-3’ 5’-CTGCTGAGTCCTCTAATAAGGC-3’ 60°C 2 min Figure 1
B2 0
1437 bp
For detection of splicing
variants
exon 1-11 5’-CGAATTTGTTAGCCGTCTCC-3’ 5’-GGATCCTGAGATATTATTTTATTATTAG-3’ 60°C 2.5 min Figure 1
C1
2118 bp
exon 10-14 5’-CTGAAGGGATGTCCAATGC-3’ 5’-GAAATTTGGATTCTGTATTTCTTG-3’ 58°C 6 min Figure 1
C2
5594 bp and 1554 bp
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0Table 1 Nucleotide base sequences of primers (Continued)
exon 11-18 5’-CTTCCTGTGAAAACAAATATAG-3’ 5’-GCTGATCTTCTGCTTTTATC-3’ 50.8°C 2 min Figure 1
C3
1417 bp
exon 15-25 5’-CCTCTGCATGTTCTCATAAAC-3’ 5’-GTGTAAGGTTTAATAATGTCTTCA-3’ 60°C 2 min Figure 1
C4
1759 bp
exon 24-27
(same as
primer set 13)
5’-CCTATCCCAAGTTTATCAGCC-3’ 5’-CAGACACAAGTTGATGTTCTCC-3’ 60°C 2 min Figure 1
C5
959 bp
For nested PCR of the
transcripts lacking most
of exon 11
exon 10-13
(1735-7280)
5’-GTTCTCAAATAATATGACTAATCCAAAC-
3’
5’-GTTCCTCAGTTGTGCGAAAG-3’ 58°C 6 min Figure 2
A
5546 bp and 1506 bp,
1185 bp, 1674 bp or
1270 bp
For DNA sequence cB2 seq1 5’-CAATAGAGGTGTTTTCTCCATC-3’
cB2 seq2 5’-GGATCCTGAGATATTATTTTATTATTAG-
3’
5546 bp and 1506 bp,
1185 bp, 1674 bp or
1270 bp
cB2 seq3 5’-CCAGCTTTGTCTTTAACCAG-3’
cB2 seq4 5’-CTGTGTGACCACTTTCACTATC-3’
cB2 seq5 5’-CCCTCCTTCATAAACTGGC-3’
cB2 seq6 5’-CTTTCTGAGAGGCATGATCTG-3’
cB2 seq7 5’-GCATGGCAAGTGTCTGATTTAC-3’
cB2 seq8 5’-GTGAACAAACTTCACAACTTAACC-3’
cB2 seq9 5’-GCTGATCTTCTGCTTTTATC-3’
cB2 seq10 5’-GGTATGTTTTACAATGATGC-3’
cB2 ex14 R
(exon)
5’-CTAAAGGTTCTTTTTCATTCTTTG-3’
cB2 ex15 F 5’- GCTTTTTAAATGTTACATGGAGG-3’
cB2 ex17 R 5’-GTACCAGTCAGGGATGTGAG-3’
cB2 ex18 F
(exon)
5’-ATATGATGTGGAAATTGATAAAA G-3’
cB2 ex22F 5’-CTTTTTAAAGGGATTCATTTACAG TGG-
3’
cB2 ex23 F
(exon)
5’-CCATCACCAGATTTATATTCCC-3’
cB2 ex26 R
(exon)
5’-CAGAAATTTATTTCCTATGCC-3’
cB2 ex23 F
(exon)
5’-CCATCACCAGATTTATATTCCC-3’
cB2 ex26 R
(exon)
5’-CAGAAATTTATTTCCTATGCC-3’
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hunds, we sequenced BRCA2 DNA from an additional 32
blood samples, and the assembled allele ratio was del:ins =
30:42 (Table 4).
We established a PCR analysis method for canine
BRCA2 in order to determine the base sequence from
cDNA and genomic DNA, and to detect splicing variants.
We identified novel splicing variants in normal canine
testes. The functions of these splicing variants were not
assessed in this study; nevertheless, these results indi-
cated that the established method was a useful tool for
detecting splicing variants.
We also defined the consensus sequence using meth-
ods established and described here. During the
definition of the consensus BRCA2 ORF, we identified
three novel (516 T > C, 2428 T > G, and 8257 T > C)
and three reported (1366 T > G, 2609A > C and 4481A
> C) single nucleotide variations and two reported inser-
tion/deletion polymorphisms (7126ins/delGTT and
10204ins/delAAA) (Accession numbers: AB622997,
AB622998 and AB622999) [11,12,15,18]. The variations
1366 T > G (C386W), 2609A > C (K801Q), 4481A > C
(T1425P), and 10204ins/delAAA (M3332IV) are located
in the histone acetyltransferase domain, the FANCG
binding domain, BRC repeat 3, and nuclear localization
signal 2, respectively [13,19-21]. The effects of these var-
iations on BRCA2 function were not understood, with
the exception of 10204insAAA; nuclear localization
Table 2 Comparison between our sequences from the canine BRCA2 open reading frame with registered sequences
Nucletide location
a 516 T > C 1366 T > G 2428 T > G 2609A > C 4481A > C 7126delGTT 8257 T > C 10204insAAA
Amino acid I103T C386W Silent K801Q T1425P 2307delL Silent M3332IK
Coding exon 3 10 11 11 11 12 18 27
Novel or reported variation Novel Reported Novel Reported Reported Reported Novel Reported
Present resequencing results
b
Full length Ovary 1 T/C G/G T/G C/A A/C ins/del T/C ins/ins
Ovary 2 T/T G/G T/T C/C A/A del/del T/T ins/ins
Testis T/T G/G T/T C/C A/A del/del T/T ins/ins
Partial Genome N. D. T:G = N. D. A:C = N. D. ins:del = N. D. del:ins =
12:30 29:15 25:15 17:29
Registered sequences
c
Ochiai et al. Testis T T T A A ins T del
Genome project Genome T T T A A ins T del
Bignell et al. Genome - - T A A - - -
Hsu et al. Mammary gl. - - T A A - - -
Total allele frequency T:C = T:G = T:G = A:C = A:C = ins:del = T:C = del:ins =
7:1 14:36 12:1 37:20 12:1 28:20 7:1 19:35
Consensus sequence 516 T 1366 G 2428 T 2609A 4481A 7126insGTT 8257 T 10204insAAA
(103I) (386 W) (740 G) (801 K) (1425 T) (2307insL) (2638I) (3332IK)
N. D., not determined.
aNucleotide and amino acid location is based on AB043895.5
bFull-length sequence was determined by cDNA sequencing (Accession number; AB622997, AB622998 and AB622999). When frequencies of major and minor
alleles were nearly equal or were inconsistent with reported sequences, alleles were further analyzed by partial sequencing of blood genome DNA from 20-23
dogs (Table 3 and 4).
cSequence from one dog was regarded as one allele because allele type analyses have not been described in these reports. The study by Hsu et al. examined
three dogs, while others studied only one dog. Accession numbers for sequences reported by Ochiai et al., the Genome Project, Bignell et al. and Hsu et al. are
AB043895.5, NC_006607.2, Z75664 and FJ464397-FJ464400, respectively.
Table 3 Genotype frequency of four variations in normal blood samples
Nucletide location
a 1366 T > G 2609A > C 7126delGTT 10204insAAA
Amino acid
a C386W K801Q 2307delL M3332IK
Coding exon 10 11 12 27
Genotype frequency 1366 T homozygosity 2/21 2609A homozygosity 10/22 insGTT homozygosity 9/20 delAAA homozygosity 5/23
1366 G homozygosity 11/21 2609 C homozygosity 3/22 delGTT homozygosity 4/20 insAAA homozygosity 11/23
Heterozygosity 8/21 Heterozygosity 9/22 Heterozygosity 7/20 Heterozygosity 7/23
aNucleotide and amino acid locations are based on AB043895.5
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Page 7 of 10Table 4 Information of blood samples and allele type of the four frequently found variations
Sample name Sex Year Breed Nucletide location
a
1366 T > G 2609A > C 7126delGTT 10204insAAA
K-1 Male 7 Beagle G/G C/C del/del ins/ins
K-2 Male 9 Labrador retriever G/G A/C ins/del ins/ins
K-3 Female 9 Mongrel dog G/T A/A ins/ins del/ins
K-4 Male 10 Bichon Frise G/T A/A ins/ins del/ins
K-5 Female 12 Pomeranian G/G A/A ins/ins ins/ins
K-6 Female 12 Puli G/T A/A ins/ins del/del
K-7 Female 6 Puli G/T A/A ins/ins del/ins
K-8 Male 10 Miniature Dachshund G/T A/C ins/del del/ins
K-9 Male 8 Miniature Dachshund G/T A/C ins/del del/del
K-10 Male 8 Miniature Dachshund T/T A/A ins/ins del/del
K-11 Female 7 Papillon G/G C/C del/del ins/ins
K-12 Female 7 Mongrel dog G/G A/A ins/ins -
K-13 Female 12 Miniature Pinscher T/T A/A ins/ins del/del
K-14 Male 14 mongrel dog G/G A/C ins/del ins/ins
K-15 Male 14 mongrel dog G/G A/A - ins/ins
K-17 Female 7 Papillon - C/C - ins/ins
K-19 Female 9 Mongrel dog G/G A/A ins/ins del/ins
K-20 Male 10 Mongrel dog G/T A/C ins/del ins/ins
K-21 Female 7 Mongrel dog G/G A/C - ins/ins
K-23 Male 10 Mongrel dog G/G A/C - del/ins
K-26 Male 15 Mongrel dog G/G A/C ins/del ins/ins
K-27 Female 9 Miniature Dachshund - A/C ins/del del/ins
K-28 Male 6 Cavalier King Charles Spaniel G/T - del/del ins/ins
K-29 Male 12 Mongrel dog - - del/del del/del
MD-1 Male 10 Miniature Dachshund - - - del/del
MD-2 Male 7 Miniature Dachshund - - - del/del
MD-3 Male 6 Miniature Dachshund - - - ins/ins
MD-4 Male 10 Miniature Dachshund - - - del/ins
MD-5 Male 12 Miniature Dachshund - - - del/ins
MD-6 Female 7 Miniature Dachshund - - - del/ins
MD-7 Male 12 Miniature Dachshund - - - del/del
MD-8 Male 11 Miniature Dachshund - - - del/ins
MD-9 Female 9 Miniature Dachshund - - - del/ins
MD-10 Male 9 Miniature Dachshund - - - ins/ins
MD-11 Male 10 Miniature Dachshund - - - del/ins
MD-12 Female 14 Miniature Dachshund - - - del/ins
MD-13 Male 9 Miniature Dachshund - - - ins/ins
MD-14 Male 6 Miniature Dachshund - - - ins/ins
MD-15 Male 6 Miniature Dachshund - - - ins/ins
MD-16 Female 7 Miniature Dachshund - - - del/ins
MD-17 Male 8 Miniature Dachshund - - - del/del
MD-18 Male 12 Miniature Dachshund - - - del/ins
MD-19 Male 10 Miniature Dachshund - - - ins/ins
MD-20 Male 6 Miniature Dachshund - - - ins/ins
MD-21 Female 6 Miniature Dachshund - - - del/ins
MD-22 Male 10 Miniature Dachshund - - - ins/ins
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Page 8 of 10signal 2 harboring the 10204insAAA variation showed
enhanced nuclear localization [13]. The other nonsynon-
ymous variations were not located in previously known
functional domains.
We identified four variations (1366 T > G, 2609A > C,
7126ins/delGTT, and 10204ins/delAAA), in which the
allele frequency of minor variations in genomic DNA
from normal blood samples was very high (28.5-37.5%).
Such frequent variations in the BRCA2 gene have not
been reported in other species. These highly frequent
variations thus appear to be a canine BRCA2-specific
feature, and should be considered when studying canine
BRCA2. These four variations were found in the homo-
zygous state in some blood samples from elderly tumor-
free dogs. Homozygous mutations in BRCA2 are
assumed to be embryonic-lethal mutations or responsi-
ble for Fanconi anemia, which is characterized by bone
marrow failure, developmental abnormalities, and pre-
disposition to cancer [22,23]. Thus, these four variations
were probably neutral variations, although the
10204insAAA variation is reportedly a candidate malig-
nant mutation in dogs [11].
In this study, we established a PCR analysis method
and defined the consensus sequence of BRCA2 ORF to
identify canine BRCA2 mutations. Using these methods,
we are now able to perform BRCA2 mutation analysis
and search for abnormal BRCA2 splicing variants from
mammary tumors in dogs, as is done in human cases.
Methods
Specimens
Two ovaries (from two mongrel dogs), six testes (from a
mongrel dog and five Beagles), a mammary gland (from
a female Beagle) and 56 blood samples (Table 4) from
tumor-free dogs were kindly provided by Dr. Takashi
Kubo and Dr. Go Honda. All experimental procedures
were approved by and conducted in accordance with the
Guidelines for Institutional Laboratory Animal Care and
Use of the School of Veterinary Medicine at Kitasato
University, Japan (Approval Number: 11-065).
Total RNA and genomic DNA extraction, and preparation
of cDNA
Total RNA was isolated from ovaries, six testes, and one
mammary gland, which each were stored in RNAlater
solution (Life Technologies,G r a n dI s l a n d ,N Y ) ,u s i n ga
TRIzol and PureLink RNA micro kit (Life Technolo-
gies). First-strand cDNA was synthesized from 1-5 μgo f
total RNA using SuperScript III (Life Technologies).
Genomic DNA samples were extracted using a Gentra
Puregene tissue kit (Qiagen, Hilden, Germany).
PCR and sequencing
For PCR amplification of the full-length canine BRCA2
ORF from cDNA and all 27 exons from genomic DNA,
we designed 14 and 20 primer sets, respectively (Table 1).
We also designed five primer sets to detect splicing var-
iants and a primer sets to confirm a novel BRCA2 tran-
script that lacked most of exon 11 using nested PCR
(Table 1). Each reaction mixture contained 0.1 μL of first-
strand cDNA reaction products or 10-50 ng of genomic
DNA as a template, each forward and reverse primer at
300 nM, 200 μM dNTPs, 0.02 U of KOD FX DNA poly-
merase (Toyobo, Japan), and 1× PCR buffer, which was
supplied with the enzyme, in a total volume of 10 μL. PCR
included one cycle of 2 min at 94°C, followed by 35 cycles
of 10 s at 98°C, 30 s at the optimal temperature shown in
Table 1 the optimal time shown in Table 1 at 68°C, and a
final extension step of 7 min at 68°C. PCR products were
treated with shrimp alkaline phosphatase (Affymetrix,
Santa Clara, CA) and Exonuclease I (New England Bio-
Labs, Beverley, MA) before sequencing, which was
performed with the BigDye Terminator Cycle Sequencing
kit Version 3.1 and a ABI PRISM 3100-Avant DNA
sequencer (Life Technologies). Direct DNA sequencing
was performed at least twice for each amplicon. When we
Table 4 Information of blood samples and allele type of the four frequently found variations (Continued)
MD-23 Female 10 Miniature Dachshund - - - del/ins
MD-24 Female 7 Miniature Dachshund - - - del/ins
MD-25 Female 7 Miniature Dachshund - - - ins/ins
MD-26 Male 8 Miniature Dachshund - - - ins/ins
MD-27 Female 9 Miniature Dachshund - - - del/ins
MD-28 Male 9 Miniature Dachshund - - - ins/ins
MD-29 Male 8 Miniature Dachshund - - - del/ins
MD-30 Male 8 Miniature Dachshund - - - del/ins
MD-31 Male 9 Miniature Dachshund - - - ins/ins
MD-32 Female 12 Miniature Dachshund - - - del/ins
aNucleotide and amino acid locations are based on AB043895.5
“-” indicates not determined.
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Page 9 of 10attempted to define the consensus canine BRCA2 ORF
sequence, two or three amplicons from each sample were
sequenced. Because we detected only three electrophero-
gram patterns among the PCR products with the inser-
tion/deletion mutation sites, we were able to determine
the heterozygous insertion/deletion mutations by direct
sequencing (Additional file 1: Figure S1).
Additional material
Additional file 1: Figure S1. Example of an electropherogram by direct
sequencing from PCR products having the insertion/deletion mutation
(7126ins/delGTT).
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